ACE Report Cover
Pain and function improved with Hyalgan in treatment of knee OA in the Asian population
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Idioma
Download Download Download
Descargar
Cite this Report Cite this Report Cite this Report
Citar
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favoritos
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Idioma
Download Download Download
Descargar
Cite this Report Cite this Report Cite this Report
Citar
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favoritos
BMC Musculoskelet Disord
OSTEOARTHRITIS
Pain and function improved with Hyalgan in treatment of knee OA in the Asian population .

OrthoEvidence Journal (OE Journal) - ACE Report

OE Journal. 2013;1(18):20

. 2011 ;():.

Autores colaboradores

TL Huang CC Chang CH Lee SC Chen CH Lai CL Tsai

200 patients were randomized to investigate the efficacy of sodium hyaluronate in the treatment of knee osteoarthritis in the Asian population. Patients were allocated to receive 5 weekly intra-articular (i.a.) injections of Hyalgan or saline placebo, and were followed-up for 20 weeks afterward. The results indicated that patients who were treated with i.a. sodium hyaluronate experienced significantly improved pain and function compared to those treated with placebo saline solution.


Detalles de la financiación de la publicación +
Financiación:
Industry funded
Patrocinador:
Hyalgan is kindly provided by Fidia Farmaceutici SpA and Med Pharma Co., Ltd.
Conflictos:
None disclosed

Riesgo de sesgo

7,5/10

Criterios de información

15/20

Índice de fragilidad

N/A

Was the allocation sequence adequately generated?

Was allocation adequately concealed?

Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?

Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?

Blinding Patients: Was knowledge of the allocated interventions adequately prevented?

Was loss to follow-up (missing outcome data) infrequent?

Are reports of the study free of suggestion of selective outcome reporting?

Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?

Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?

Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?

Sí = 1

Incierto = 0,5

No relevante = 0

No = 0

La evaluación de los criterios de información evalúa la transparencia con la que los autores informan de las características metodológicas y del ensayo dentro de la publicación. La evaluación se divide en cinco categorías que se presentan a continuación.

2/4

Randomization

3/4

Outcome Measurements

4/4

Inclusion / Exclusion

2/4

Therapy Description

4/4

Statistics

Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65

El Índice de Fragilidad es una herramienta que ayuda en la interpretación de hallazgos significativos, proporcionando una medida de fuerza para un resultado. El Índice de Fragilidad representa el número de eventos consecutivos que es necesario añadir a un resultado dicotómico para que el hallazgo deje de ser significativo. Un número pequeño representa un hallazgo más débil y un número grande un hallazgo más fuerte.

¿Por qué se necesitaba ahora este estudio?

Common primary treatment of knee osteoarthritis usually consists of simple analgesics, but when pain can no longer be effectively reduced, a therapy of nonsteroidal anti-inflammatory drugs (NSAIDs) is adopted. Although NSAIDs possess well documented pain relief and anti-inflammatory effects, serious gastrointestinal side-effects have been reported with their use. A preferential alternative to NSAIDs has been intra-articular injections of sodium hyaluronate (Hyalgan), but despite extensive research on a worldwide scale, only one study has been dedicated to investigating the efficacy of such treatment in an Asian population.

¿Cuál era la pregunta principal de la investigación?

Did 5 weekly intra-articular injections of 20-mg/2mL sodium hyaluronate effectively reduce pain compared to 2mL of placebo saline solution, when measured after 25 weeks from the beginning of therapy?

Características del estudio +
Población:
200 patients diagnosed with knee osteoarthritis based on American College of Rheumatology (ACR) criteria (knee pain with at least one of the following conditions: >50 years old, crepitus, or morning stiffness <30 minutes in duration). (n=176 completed follow-up)
Intervención:
Hyalgan group: Patients received intra-articular injection of sodium hyaluronate (20-mg/2mL) once a week for 5 weeks. (n=88 completed follow-up)
Comparación:
Placebo group: Patients received intra-articular injection of saline placebo (2mL) once a week for 5 weeks. (n=88 completed follow-up)
Resultados:
Primary outcome was pain reduction on a 100-mm visual analog scale (VAS) during the 50-foot walking test. Secondary outcomes were pain, stiffness, and function through subsections of the Western Ontario McMaster Universities Arthritis Index (WOMAC), time required to complete the 50-foot walking test, synovial effusion volume of the knee, patient and investigator subjective scoring of effectiveness (scale 1 to 6), and acetaminophen consumption.
Métodos:
RCT, Double Blind, Multicenter, Placebo-controlled, Prospective
Tiempo:
Evaluation was conducted at baseline, 5 weeks (ie. end of injections), 13 and 25 weeks.
¿Cuáles fueron los hallazgos importantes?
  • Pain (VAS) on the 50 foot walking test was reduced from 45.15mm to 21.53mm (baseline to week 25) in the placebo group and 47.85mm to 17.00mm in the Hyalgan group. The difference in pain at week 25 (P=0.035) and the overall reduction of pain (0.002) were statistically significant, favoring the Hyalgan group.
  • Pain and function, as assessed by WOMAC subscales, was significantly reduced with sodium hyaluronate compared to the placebo (P=0.0050 and 0.0038, respectively). Significance was detected by week 5 and carried through for the remainder of the study.
  • Although WOMAC stiffness scores were generally more improved in the Hyalgan group, there was no significant difference in this outcome between groups for the duration of the study.
  • Both groups achieved slight reduction from baseline 50-foot walking test, with no significant difference.
  • No difference was observed in the amount of synovial fluid of the knee between treatment groups.
  • Patient and investigator rating of therapy effectiveness did not significantly differ between groups.
  • There was no difference in acetaminophen consumption between groups for the duration of the study.
¿Qué es lo que más debo recordar?

The 5-injection administration of 20-mg/mL sodium hyaluronte provided improved pain (100-mm and WOMAC subscale) and function (WOMAC subscale) compared to saline placebo in an Asian population. Difference was detected after 5 weeks and held through to the end of the study at 25 weeks.

¿Cómo afectará esto al cuidado de mis pacientes?

The results of this study support the use of sodium hyaluronate for the treatment of knee osteoarthritis in the Asian population. For a more robust understanding of the efficacy of Hyalgan in the Asian population, future studies should consider outcomes in the long-term and employ Minimum Important Differences (MIDs).

DESCARGO DE RESPONSABILIDAD

El contenido de esta página tiene únicamente fines informativos y no pretende sustituir el consejo, diagnóstico o tratamiento médico profesional. Si necesita tratamiento médico, busque siempre el consejo de su médico o acuda al servicio de urgencias más cercano. Las opiniones, creencias y puntos de vista expresados por las personas sobre el contenido que se encuentra en esta página no reflejan las opiniones, creencias y puntos de vista de OrthoEvidence.

0 de 4 artículos mensuales GRATIS desbloqueados
Ha alcanzado su límite de vistas de 4 artículos gratuitos este mes

Acceda a OrtoEvidencia por tan sólo 1,99 $ a la semana.

Manténgase conectado con las últimas pruebas. Cancele en cualquier momento.
  • Valoraciones críticas de los últimos ensayos controlados aleatorizados de gran impacto y revisiones sistemáticas en ortopedia
  • Acceso al contenido del podcast OrthoEvidence, que incluye colaboraciones con el Journal of Bone and Joint Surgery, entrevistas con cirujanos reconocidos internacionalmente y mesas redondas sobre noticias y temas ortopédicos
  • Suscripción a The Pulse, un boletín quincenal basado en la evidencia y diseñado para ayudarle a tomar mejores decisiones clínicas
Upgrade
Close Dialog
Bienvenido
¿Ha olvidado su contraseña?
Comience hoy mismo su prueba GRATUITA

Su cuenta estará afiliada a
e incluye acceso gratuito a OrthoEvidence


O
¿Olvidó su contraseña?

O
Compruebe su correo electrónico

Si existe una cuenta con la dirección de correo electrónico proporcionada, se le enviará un correo electrónico para restablecer la contraseña. Si no ve el correo electrónico, compruebe su carpeta de correo no deseado o spam.

Si necesita más ayuda póngase en contacto con nuestro equipo de asistencia.

Inicie sesión para activar esta función

Para acceder a esta función, debe iniciar sesión en una cuenta activa de OrthoEvidence. Por favor, inicie sesión o cree una cuenta de prueba GRATUITA.

Traducir Informe ACE

OrthoEvidence utiliza un servicio de traducción de terceros para que el contenido sea accesible en varios idiomas. Tenga en cuenta que, aunque se hace todo lo posible para garantizar la exactitud, las traducciones no siempre son perfectas.

Cómo citar esto ACE Report

OrthoEvidence. Pain and function improved with Hyalgan in treatment of knee OA in the Asian population. OE Journal. 2013;1(18):20. Available from: https://myorthoevidence.com/AceReport/Show/pain-and-function-improved-with-hyalgan-in-treatment-of-knee-oa-in-the-asian-population

Copiar cita
Inicie sesión para activar esta función

Para acceder a esta función, debe iniciar sesión en una cuenta activa de OrthoEvidence. Por favor, inicie sesión o cree una cuenta de prueba GRATUITA.

Función de miembro Premium

Para acceder a esta función, debe iniciar sesión en una cuenta Premium de OrthoEvidence.

Compartir ACE Report